INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $107,503,448 | -14.1% | 2,063,802 | +4.4% | 0.01% | -14.3% |
| Q2 2023 | $125,209,854 | +26.3% | 1,977,414 | +8.0% | 0.01% | +16.7% |
| Q1 2023 | $99,143,000 | +124971.6% | 1,830,884 | +22.2% | 0.01% | +20.0% |
| Q4 2022 | $79,269 | -99.1% | 1,497,914 | +697.7% | 0.01% | +900.0% |
| Q3 2022 | $8,738,000 | -19.1% | 187,784 | -0.8% | 0.00% | -50.0% |
| Q2 2022 | $10,800,000 | +12.3% | 189,217 | +20.4% | 0.00% | +100.0% |
| Q1 2022 | $9,615,000 | +30.6% | 157,144 | +11.7% | 0.00% | 0.0% |
| Q4 2021 | $7,364,000 | +39.1% | 140,690 | -0.9% | 0.00% | 0.0% |
| Q3 2021 | $5,293,000 | -10.0% | 142,003 | -1.5% | 0.00% | 0.0% |
| Q2 2021 | $5,881,000 | +16.0% | 144,094 | -3.6% | 0.00% | 0.0% |
| Q1 2021 | $5,070,000 | -0.1% | 149,403 | -6.4% | 0.00% | 0.0% |
| Q4 2020 | $5,075,000 | +21.5% | 159,603 | -2.4% | 0.00% | 0.0% |
| Q3 2020 | $4,177,000 | -2.1% | 163,543 | -1.6% | 0.00% | 0.0% |
| Q2 2020 | $4,268,000 | +69.4% | 166,262 | +1.4% | 0.00% | 0.0% |
| Q1 2020 | $2,520,000 | -80.6% | 164,001 | -56.8% | 0.00% | -50.0% |
| Q4 2019 | $13,014,000 | +711.3% | 379,319 | +76.6% | 0.00% | – |
| Q3 2019 | $1,604,000 | -40.0% | 214,824 | +2.0% | 0.00% | -100.0% |
| Q2 2019 | $2,675,000 | +0.9% | 210,531 | -3.2% | 0.00% | 0.0% |
| Q1 2019 | $2,651,000 | -6.7% | 217,576 | -12.8% | 0.00% | 0.0% |
| Q4 2018 | $2,841,000 | -39.7% | 249,400 | +14.8% | 0.00% | 0.0% |
| Q3 2018 | $4,714,000 | +4.0% | 217,232 | -15.3% | 0.00% | 0.0% |
| Q2 2018 | $4,532,000 | -43.9% | 256,495 | -33.2% | 0.00% | -50.0% |
| Q1 2018 | $8,078,000 | +7.8% | 383,770 | -25.8% | 0.00% | 0.0% |
| Q4 2017 | $7,491,000 | +18.7% | 517,307 | +26.7% | 0.00% | +100.0% |
| Q3 2017 | $6,310,000 | +620.3% | 408,425 | +657.5% | 0.00% | – |
| Q1 2017 | $876,000 | -39.2% | 53,915 | -43.6% | 0.00% | – |
| Q4 2016 | $1,441,000 | +4138.2% | 95,539 | +4242.7% | 0.00% | – |
| Q3 2016 | $34,000 | -99.4% | 2,200 | -98.5% | 0.00% | -100.0% |
| Q2 2016 | $5,678,000 | +332.4% | 146,276 | +209.7% | 0.00% | – |
| Q1 2016 | $1,313,000 | -32.4% | 47,225 | +30.7% | 0.00% | – |
| Q4 2015 | $1,943,000 | – | 36,128 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |